Antithrombotic therapy in patients with atrial fibrillation after percutaneous coronary intervention

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Patients undergoing percutaneous coronary intervention (PCI) with stenting often require dual antiplatelet therapy (DAPT).
• Coexisting indications for oral anticoagulation (OAC), such as atrial fibrillation (AF), necessitate triple antithrombotic therapy (TAT), raising concerns about excessive bleeding.
• The optimal balance between bleeding risk and ischemic event prevention in patients on TAT is a subject of ongoing research.

Purpose of the Study:

• To review landmark clinical trials and meta-analyses comparing TAT with dual antithrombotic therapy (DAT).
• To outline current international recommendations for antithrombotic regimens in patients with coexisting PCI and OAC indications.
• To identify unresolved issues and future research directions in managing antithrombotic therapy.

Main Methods:

• Review of pivotal clinical trials comparing TAT with DAT.
• Analysis of subsequent meta-analyses of these trials.
• Examination of international guidelines and expert opinions on antithrombotic strategies.

Main Results:

• Current recommendations often favor a short duration of TAT, typically with clopidogrel, followed by aspirin withdrawal.
• Emerging evidence suggests that ticagrelor or prasugrel may provide more consistent P2Y12 inhibition.
• Ticagrelor monotherapy has shown promise in post-PCI patients without OAC indications.

Conclusions:

• Dual antithrombotic therapy (DAT) using ticagrelor or prasugrel immediately post-PCI may represent a safer and more effective alternative to clopidogrel-based regimens in select patients.
• Further trials are needed to establish optimal antithrombotic strategies balancing efficacy and safety.
• Personalized antithrombotic regimens are essential for patients with complex cardiovascular conditions.